Cytomegalovirus (CMV) resistance in patients with CMV retinitis and AIDS treated with oral or intravenous ganciclovir

Journal of Infectious Diseases

Volumn 179, Issue 6, 1999, Pages 1352-1355

  Drew, W Lawrence ^a,b   Stempien, Mary Jean ^a,b,c   Andrews, Jodi ^a,b   Shadman, Anna ^a,b   Tan, Shu Jane ^a,b   Miner, Richard ^a,b   Buhles, William ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ROCHE BIOSCIENCE   (United States)

^c Roche Global Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CYTOMEGALOVIRUS INFECTION; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; RETINITIS; VIRUS ISOLATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS RETINITIS; DRUG RESISTANCE, MICROBIAL; GANCICLOVIR; HUMANS; INHIBITORY CONCENTRATION 50; INJECTIONS, INTRAVENOUS; TIME FACTORS;

EID: 0033038929     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314747     Document Type: Article

References (12)

1. 1. Koretz SH, Buhles WC, Brewin A, et al. Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies. N Engl J Med 1986;314: 801-5.
2. 2. Erice A, Chou S, Biron K, et al. Progressive disease due to ganciclovi-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989;320:289-93.
3. 3. Drew WL, Miner RC, Busch DF, et al. Frequency of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991;163:716-9.
4. 4. Drew WL, Miner R, Saleh E. Antiviral susceptibility testing of cytomegalovirus: criteria for detecting resistance to antivirals. Clin Diagn Virol 1993;1:179-85.
5. 5. Jabs DA, Enger C, Dunn JP, Forman M for the CMV Retinitis and Viral Resistance Study Group. Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. J Infect Dis 1998;177:770-3.
6. 6. Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995;333:615-20.
7. 7. Spector SA, McKinley GF, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS, N Engl J Med 1996;334:1491-7.
8. 8. Gane E, Saliba F, Valdecasas G, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997;350:1729-33.
9. 9. Spector SA, Busch DF, Follansbee S, et al. Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: s phase I/II study. J Infect Dis 1995;171:1431-7.
10. 10. Squires KE, Stempien MJ, Shadman A, et al. Oral ganciclovir (POG) versus intravenous ganciclovir (IVG) maintenance therapy for cytomegalovirus (CMV) retinitis in patients with AIDS: preliminary results of a phase III study [abstract 540]. In: 1st National Conference on Human Retroviruses and Related Infections: program and abstracts (Washington, DC). Washington, DC: American Society for Microbiology, 1993:154.
11. 11. Lalezari J, Friedberg D, Bisset J, et al. A comparison of the safely and efficacy of 3 G, 4.5 G, and 6 G doses of oral ganciclovir versus iv ganciclovir for maintenance treatment of CMV relinilis [abstract Th.B.305]. In: Program and abstracts: XI International Conference on AIDS (Vancouver, Canada). Vancouver: XI International Conference on AIDS Society, 1996.
12. 12. Drug resistance in cytomegalovirus: current knowledge and implications for patient management. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12(Suppl 1):S1-22.